<DOC>
	<DOCNO>NCT00007332</DOCNO>
	<brief_summary>The purpose study see vaccine test safe give alone give together , immune system respond vaccine . Vaccines give people try prevent infection disease . Early test people show HIV vaccine ALVAC vCP1452 AIDSVAX B/B seem safe use .</brief_summary>
	<brief_title>Safety Immune Response Study Vaccine ALVAC vCP1452 Alone Combination With AIDSVAX B/B</brief_title>
	<detailed_description>There cure HIV infection AIDS , drug therapy expensive affected population . For reason , development safe , effective vaccine prevent HIV infection worldwide need . ALVAC vCP1452 MN rgp120/HIV-1 show well tolerated Phase I II study . ALVAC vCP1452 give alone combination subunit antigens [ AS PER AMENDMENT 10/12/00 : antigen ] candidate vaccine evaluate ability produce express vaccine antigen great quantity long time improved immunogenicity . Volunteers randomize 1 7 [ AS PER AMENDMENT 10/12/00 : 1 4 ] group stratify risk status . Prior immunization , evaluation blood draws do monitor hematological , chemical , immunologic parameter . Volunteers receive 2 injection follow vaccine Months 0 , 1 , 3 , 6 : Group A : ALVAC vCP1452 alum placebo [ AS PER AMENDMENT 10/12/00 : AIDSVAX placebo ( aluminum hydroxide adjuvant ) ] Months 0 , 1 , 3 , 6 . Group B : ALVAC vCP1452 alum placebo [ AS PER AMENDMENT 10/12/00 : AIDSVAX placebo ] Months 0 1 ALVAC vCP1452 AIDSVAX B/B Months 3 6 . Group C : ALVAC placebo alum placebo . [ AS PER AMENDMENT 10/12/00 : ALVAC vCP1452 AIDSVAX B/B Months 0 , 1 , 6 ALVAC vCP1452 AIDSVAX placebo Month 3 . ] Group D : ALVAC vCP1452 alum placebo Months 0 1 ALVAC vCP1452 MN rgp120 Months 3 6 . [ AS PER AMENDMENT 10/12/00 : ALVAC placebo AIDSVAX placebo Months 0 , 1 , 3 , 6 . ] Group E : ALVAC vCP1452 AIDSVAX B/B Months 0 , 1 , 6 ; ALVAC vCP1452 alum placebo Month 3 . [ AS PER AMENDMENT 10/12/00 : Group E discontinue . ] Group F : ALVAC vCP1452 AIDSVAX B/B . [ AS PER AMENDMENT 10/12/00 : Group F discontinue . ] Group G : ALVAC vCP1452 alum placebo Months 0 1 ; ALVAC vCP1452 AIDSVAX B/E Months 3 6 . [ AS PER AMENDMENT 10/12/00 : Group G discontinue . ] Following pair injection , volunteer observe clinic 30 minute . Volunteers keep record body temperature symptom report result AIDS Vaccine Evaluation Unit . Evaluations perform telephone clinic visit Days 1 2 vaccination . [ AS PER AMENDMENT 10/12/00 : Volunteers record relevant sign symptom occur 48 hour vaccination provide information clinic visit . ] HIV testing conduct every 3 6 month volunteer ask complete social harm questionnaire Day 168 end study . Volunteers follow study minimum 18 month first immunization . Safety evaluate closely monitoring local systemic adverse reaction course trial .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Volunteers may eligible study : Are HIVnegative . Are 18 60 year old . Have CD4 cell count 400 cells/mm3 . Agree use adequate birth control 1 month study entry study ( female participant ) . Have normal history physical examination . Are available 12 month followup plan duration study . Have negative pregnancy test within 3 day prior injection . Exclusion Criteria Volunteers eligible study : Are pregnant breastfeeding . Have chronic hepatitis B . Are take medication affect immune system . Have immune system problem , longterm illness , autoimmune disease . Have cancer , except remove surgery cure likely . Have physical condition , mental condition , job work may interfere study . Have suicidal , ever need medicine serious mental condition . Have receive certain vaccine within 60 day study entry . Have use experimental drug within 30 day prior study entry . Have receive blood product , immunoglobulin , last 6 month . Have active syphilis . Have active tuberculosis . Have history severe allergy serious reaction vaccine . Have HIV1 vaccine clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>CD8-Positive T-Lymphocytes</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>AIDSVAX</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>